Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

DESTINY Breast Respond HER2-(Ultra)Low Europe

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
unresectable breast cancer, metastatic breast cancer, her2-low expressing breast cancer, her2-(ultra)low expressing breast cancer, trastuzumab deruxtecan, enhertu®, observational
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 806685
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.